Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 373, Issue 2, 2006, Pages 169-181

  Luszczki, Jarogniew J ^a   Ratnaraj, Neville ^b   Patsalos, Philip N ^b   Czuczwar, Stanislaw J ^a,c  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Carbamazepine; Drug interactions; Isobolographic analysis; Loreclezole; Maximal electroshock; Pharmacokinetic interactions; Phenobarbital; Phenytoin; Valproate

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ANTICONVULSIVE AGENT; CARBAMAZEPINE; LORECLEZOLE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; BRAIN HOMOGENATE; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG MECHANISM; DRUG POTENTIATION; ELECTRIC SHOCK; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOBOLOGRAPHIC ANALYSIS; LEARNING; LINEAR REGRESSION ANALYSIS; LONG TERM MEMORY; MALE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PASSIVE AVOIDANCE; PHARMACODYNAMICS; SEIZURE; SEIZURE THRESHOLD;

ALGORITHMS; ANIMALS; ANTICONVULSANTS; AVOIDANCE LEARNING; BRAIN; DRUG INTERACTIONS; DYSKINESIA, DRUG-INDUCED; ELECTROSHOCK; EPILEPSY, GENERALIZED; EPILEPSY, TONIC-CLONIC; MALE; MEMORY; MICE; PSYCHOMOTOR PERFORMANCE; SEIZURES; TRIAZOLES;

EID: 33646703115     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-006-0055-4     Document Type: Conference Paper

References (69)

1. Ashton D, Fransen J, Heeres J, Clincke GH, Janssen PA (1992) In vivo studies on the mechanism of action of the broad spectrum anticonvulsant loreclezole. Epilepsy Res 11:27-36
2. Ates N, Van Luijtelaar EL, Drinkenburg WH, Vossen JM, Coenen AM (1992) Effects of loreclezole on epileptic activity and on EEG and behaviour in rats with absence seizures. Epilepsy Res 13:43-48
3. Barker JL, McBurney RN (1979) Phenobarbitone modulation of postsynaptic GABA receptor function on cultured mammalian neurons. Proc R Soc Loud B Biol Sci 206:319-327
4. Besag FM, Berry DJ, Pool F, Newbery JE, Subel B (1998) Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia 39:183-187
5. Boissier JR, Tardy J, Diverres JC (1960) Une nouvelle méthode simple pour explorer l'action tranquilisante: le test de la cheminée. Med Exp (Basel) 3:81-84
6. Borowicz KK, Kleinrok Z, Czuczwar SJ (2000) The AMPA/kainate receptor antagonist, LY 300164, increases the anticonvulsant effects of diazepam. Naunyn Schmiedebergs Arch Pharmacol 361:629-635
7. Borowicz KK, Swiader M, Luszczki J, Czuczwar SJ (2002) Effect of gabapentin on the anticonvulsant activity of antiepileptic drugs against electroconvulsions in mice - an isobolographic analysis. Epilepsia 43:956-963
8. Borowicz KK, Sawiniec A, Czuczwar SJ (2004) Interaction of loreclezole with conventional antiepileptic drugs in amygdala-kindled rats. Eur Neuropsychopharmacol 14:251-257
9. Cadart M, Marchand S, Pariat C, Bouquet S, Couet W (2002) Ignoring pharmacokinetics may lead to isoboles misinterpretation: illustration with the norfloxacin-theophylline convulsant interaction in rats. Pharm Res 19:209-214
10. Czuczwar SJ, Borowicz KK (2002) Polytherapy in epilepsy: the experimental evidence. Epilepsy Res 52:15-23
11. De Beukelaar F, Tritsmans L (1991) Loreclezole. In: Pisani F, Perucca E, Avanzini G, Richens A (eds) New Antiepileptic Drugs. (Epilepsy Research Suppl. 3). Elsevier Science Publishers, Amsterdam, pp 125-128
12. Deckers CL, Czuczwar SJ, Hekster YA, Keyser A, Kubova H, Meinardi H, Patsalos PN, Renier WO, Van Rijn CM (2000) Selection of antiepileptic drug polytherapy based on mechanism of action: the evidence reviewed. Epilepsia 41:1364-1374
13. Deckers CL, Genton P, Sills GJ, Schmidt D (2003) Current limitations of antiepileptic drug therapy: a conference review. Epilepsy Res 53:1-17
14. Della Paschoa OE, Hoogerkamp A, Edelbroek PM, Voskuyl RA, Danhof M (2000) Pharmacokinetic-pharmacodynamic correlation of lamotrigine, flunarizine, loreclezole, CGP40116 and CGP39551 in the cortical stimulation model. Epilepsy Res 40:41-52
15. Donnelly JL, Macdonald RL (1996) Loreclezole enhances apparent desensitization of recombinant GABAA receptor currents. Neuropharmacology 35:1233-1241
16. Gasior M, Ungard JT, Witkin JM (1999) Preclinical evaluation of newly approved and potential antiepileptic drugs against cocaine-induced seizures. J Pharmacol Exp Ther 290:1148-1156
17. Genton P, Roger J (1997) Antiepileptic drug monotherapy versus polytherapy: a historical perspective. Epilepsia 38(Suppl.5):S2-S5
18. A receptor in rat brain. Biochem Pharmacol 51:1527-1534
19. Glantz SA, Slinker BK (2001) Primer of applied regression & analysis of variance. 2nd ed. McGraw-Hill Inc., New York
20. Jozwiak S, Terczynski A (2000) Open study evaluating lamotrigine efficacy and safety in add-on treatment and consecutive monotherapy in patients with carbamazepine- or valproate-resistant epilepsy. Seizure 9:486-492
21. Krämer G (1997) The limitations of antiepileptic drug monotherapy. Epilepsia 38(Suppl.5):S9-S13
22. Kwan P, Brodie MJ (2000a) Early identification of refractory epilepsy. New Engl J Med 342:314-319
23. Kwan P, Brodie MJ (2000b) Epilepsy after the first drug fails: substitution or add-on? Seizure 9:464-468
24. Leppik IE (2001) Antiepileptic drugs. In: Leppik IE (ed) Contemporary diagnosis and management of the patients with epilepsy. 5th edition. Handbooks in Health Care Co., Newton, Pennsylvania, pp 74-116
25. Litchfield JT, Wilcoxon F (1949) A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96:99-113
26. Loewe S (1953) The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3:285-290
27. Lohn YI, Ratnaraj N, Hjelm M, Patsalos PN (1994) Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: Phenytoin. Epilepsy Res 19:99-110
28. Löscher W, Nolting B (1991) The role of technical, biological and pharmacological factors in the laboratory evaluation of anti-convulsant drugs. IV. Protective indices. Epilepsy Res 9:1-10
29. Löscher W, Schmidt D (1988) Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 2:145-181
30. Löscher W, Fassbender CP, Nolting B (1991) The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res 8:79-94
31. Luszczki JJ, Czuczwar SJ (2003) Isobolographic and subthreshold methods in the detection of interactions between oxcarbazepine and conventional antiepileptics-a comparative study. Epilepsy Res 56:27-42
32. Luszczki JJ, Czuczwar SJ (2004a) Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study. Naunyn Schmiedeberg's Arch Pharmacol 369:434-446
33. Luszczki JJ, Czuczwar SJ (2004b) Three-dimensional isobolographic analysis of interactions between lamotrigine and clonazepam in maximal electroshock-induced seizures in mice. Naunyn-Schmiedeberg's Arch Pharmacol 370:369-380
34. Luszczki JJ, Czuczwar SJ (2005a) Interaction between lamotrigine and felbamate in the maximal electroshock-induced seizures in mice: an isobolographic analysis. Eur Neuropsychopharmacol 15:133-142
35. Luszczki JJ, Czuczwar SJ (2005b) How significant is the difference between drug doses influencing the threshold for electroconvulsions? Pharmacol Rep 57:782-786
36. Luszczki JJ, Borowicz KK, Swiader M, Czuczwar SJ (2003a) Interactions between oxcarbazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 44:489-499
37. Luszczki JJ, Czuczwar M, Kis J, Krysa J, Pasztelan I, Swiader M, Czuczwar SJ (2003b) Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 44:1003-1013
38. Luszczki JJ, Swiader M, Parada-Turska J, Czuczwar SJ (2003c) Tiagabine synergistically interacts with gabapentin in the electroconvulsive threshold test in mice. Neuropsychopharmacology 28:1817-1830
39. Luszczki JJ, Swiader M, Czuczwar M, Kis J, Czuczwar SJ (2003d) Interactions of tiagabine with some antiepileptics in the maximal electroshock in mice. Pharmacol Biochem Beh 75:319-327
40. Luszczki JJ, Wojcik-Cwikla J, Andres M, Czuczwar SJ (2005a) Pharmacological and behavioral characteristics of interactions between vigabatrin and conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis. Neuropsychopharmacology 30:958-973
41. Luszczki JJ, Ratnaraj N, Patsalos PN, Czuczwar SJ (2005b). Pharmacodynamic and/or pharmacokinetic characteristics of interactions between loreclezole and four conventional antiepileptic drugs in pentylenetetrazole- induced seizures in mice: An isobolographic analysis. Epilepsy Behav 7:639-651
42. MacDonald RL, Rogers CJ, Twyman RE (1989) Barbiturate regulation of kinetic properties of the GABAA receptor channel of mouse spinal neurones in culture. J Physiol 417:483-500
43. Parada J, Czuczwar SJ, Turski WA (1992) NBQX does not affect learning and memory tasks in mice: a comparison with D-CPPene and ifenprodil. Brain Res Cogn Brain Res 1:67-71
44. Parada-Turska J, Turski WA (1990) Excitatory amino acid antagonists and memory: effect of drugs acting at N-methyl-D-aspartate receptors in learning and memory tasks. Neuropharmacology 29:1111-1116
45. Patsalos PN (2005) Anti-epileptic drug interactions. A clinical guide. Clarius Press, Guildford, UK
46. Patsalos PN, Perucca E (2003a) Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2:347-356
47. Patsalos PN, Perucca E (2003b) Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2:473-481
48. Patsalos PN, Fröscher W, Pisani F, Van Rijn CM (2002) The importance of drug interactions in epilepsy therapy. Epilepsia 43:365-385
49. Perucca E (1995) Pharmacological principles as a basis for polytherapy. Acta Neurol Scand Suppl. 162:31-34
50. Pietrasiewicz T, Czechowska G, Dziki M, Turski WA, Kleinrok Z, Czuczwar SJ (1993) Competitive NMDA receptor antagonists enhance the antielectroshock activity of various antiepileptics. Eur J Pharmacol 250:1-7
51. Pohl M, Mares P (1990) Effects of loreclezole on metrazol-induced phenomena in developing rats. Arch Int Pharmacodyn Ther 305:163-171
52. Porreca F, Jiang Q, Tallarida RJ (1990) Modulation of morphine antinociception by peripheral [Leu5]enkephalin: a synergistic interaction. Eur J Pharmacol 179:463-468
53. Rentmeester T, Hulsman J (1991) Efficacy and safety evaluation of loreclezole as add-on treatment in therapy-resistant epilepsy patients. Epilepsy Res 8:166-169
54. Rentmeester T, Hulsman J (1992) Loreclezole monotherapy in patients with partial seizures. Epilepsy Res 11:141-145
55. Rentmeester T, Janssen A, Hulsman J, Scholtes F, Van Der Kleij B, Overweg J, Meijer J, De Beukelaar F (1991a) A double-blind, placebo-controlled evaluation of the efficacy and safety of loreclezole as add-on therapy in patients with uncontrolled partial seizures. Epilepsy Res 9:59-64
56. Rentmeester T, Janssen A, Hulsman J, Scholtes F, Van Der Kleij B, Overweg J, Meijer J, De Beukelaar F (1991b) Long-term evaluation of the efficacy and safety of loreclezole as add-on therapy in patients with uncontrolled partial seizures: a 1-year open follow-up. Epilepsy Res 9:65-70
57. Reynolds EH, Shorvon SD (1981) Single drug or combination therapy for epilepsy? Drugs 21:374-382
58. Rho JM, Donevan SD, Rogawski MA (1996) Direct activation of GABAA receptors by barbiturates in cultured rat hippocampal neurons. J Physiol 497(Pt 2):509-522
59. Roks G, Deckers CLP, Meinardi H, Egmond JV, Van Rijn CM (1999) Effect of polytherapy compared with monotherapy in antiepileptic drug: an animal study. J Pharmacol Exp Ther 288:472-477
60. A receptors by loreclezole, an anticonvulsant drug with selectivity for the beta-subunit. Neuropharmacology 35:1753-1760
61. Schmidt D (1996) Modern management of epilepsy: Rational polytherapy. Baillieres Clin Neurol 5:757-763
62. Stephen LJ, Brodie MJ (2002) Seizure freedom with more than one antiepileptic drug. Seizure 11:349-351
63. Tallarida RJ (2000) Drug synergism and dose-effect data analysis. Chapman & Hall/CRC, Boca Raton
64. Tallarida RJ, Stone DJ, Raffa RB (1997) Efficient designs for studying synergistic drug combinations. Life Sci 61:PL417-PL425
65. Thomet U, Baur R, Dodd RH, Sigel E (2000) Loreclezole as a simple functional marker for homomeric rho type GABA(C) receptors. Eur J Pharmacol 408:R1-R2
66. Venault P, Chapouthier G, De Carvalho LP, Simiand J, Morre M, Dodd RH, Rossier J (1986) Benzodiazepines impair and beta-carbolines enhance performance in learning and memory tasks. Nature 321:864-866
67. Wafford KA, Bain CJ, Quirk K, Mckeman RM, Wingrove PB, Whiting PJ, Kemp JA (1994) A novel allosteric modulatory site on the GABAA receptor beta subimit. Neuron 12:775-782
68. Wingrove PB, Wafford KA, Bain C, Whiting PJ (1994) The modulatory action of loreclezole at the gamma-aminobutyric acid type A receptor is determined by a single amino acid in the beta 2 and beta 3 subunit. Proc Natl Acad Sci USA 91:4569-4573
69. White HS, Woodhead JH, Wilcox KS, Stables JP, Kupferberg HJ, Wolf HH (2002) Discovery and preclinical development of antiepileptic drugs. In: Levy RH, Mattson RH, Meldrum BS, Perucca E (eds) Antiepileptic drugs, 5th ed. Lippincott Williams & Wilkins, Philadelphia, pp 36-48